Ripamonti Ugo
The Department of internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Biomater Adv. 2025 Jul;172:214262. doi: 10.1016/j.bioadv.2025.214262. Epub 2025 Mar 2.
This perspective article proposes that the induction of bone by recombinant human bone morphogenetic proteins (hBMPs), and by the recombinant human transforming growth factor-β (hTGF-β), the latter only in primates, recapitulates embryonic development, whereby large ossicles de novo form in heterotopic intramuscular sites, where several responding cells are available with marked vascular invasion. The induction of bone initiates with the induction of cartilage' anlages recapitulating development. Selected recombinant hBMPs, hBMP-2 and hOP-1 (hBMP-7) on the other hand, fail to induce significant osteoinduction in orthotopic intraskeletal sites in clinical contexts. This review proposes that the failure of significant clinical bone formation in orthotopic sites is because implantation of hBMP-2 and hOP-1, as well as hTGF-β in human mandibular sites, does not proceed via recapitulation of embryonic development, ultimately failing the clinical translation of the "bone induction principle". Biologically, a prerogative of the osteogenic proteins of the TGF-β super family, is the heterotopic induction of bone that initiates via recapitulation of embryonic bone development. Delivery of recombinant hBMP-2 and/or hOP-1 into human bony defects fails because the induction of bone is possible only via embryonic development, which does not occur in orthotopic sites, with limited responding cells and vascular supply. The initiation and assembly of the bone/bone-marrow organ follow a multistep molecular and cellular cascades that ultimately morphogenize the assembly of skeletogenesis masterminding ambulation, body erection, masticatory functions, copulation and the preservation of vital organs and tissues such as the marrow and the cerebral hemispheres. Embryologically, bone forms either via mesenchymal osteogenesis or via endochondral osteogenesis. The former route prevalently sculpts the craniomandibulofacial bones by inducing aggregation of targeted mesenchymal cells to condensate in the primordia of the craniofacial skeleton. A critical step is the condensation of mesenchymal cells that forms around vessels, as the vessels guide the formation of bone. Endochondral osteogenesis initiates by firstly constructing cartilage' anlages that developing bone uses as struts to growth and differentiate. The cartilage anlage is an extraordinary conduit that sets into motion molecular and cellular cell-to-cell, cell-to-receptors cross-talking to initiate angiogenesis and capillary invasion within the hypertrophic cartilage, chondrolysis that initiate osteoblastic cellular differentiation and the deposition of bone, osteoid synthesis, bone marrow development and the induction of a complete mineralized bone-bone marrow organ. The assembled constructs are storage of critical ions, several structural proteins such as osteonectins and fibronectins, biological markers of osteoblast' secretion and activity, such as osteocalcin, together with an array of extraordinary morphogen initiators that de novo set into motion the molecular and cellular cascades inducing bone in heterotopic sites recapitulating embryonic development. In evolutionary molecular biology contexts however, the pleiotropic activities of both proteins' family and the induction of bone formation in heterotopic sites are developmental, and thus not suitable to induce bone when recombinant morphogens are singly implanted in orthotopic skeletal defects, the latter lacking the developmental biological platform.
这篇观点文章提出,重组人骨形态发生蛋白(hBMPs)以及重组人转化生长因子-β(hTGF-β,后者仅在灵长类动物中)诱导骨形成的过程重现了胚胎发育,即大的听小骨在异位肌内部位从头形成,该部位有几种反应性细胞且有明显的血管侵入。骨诱导始于软骨原基的诱导,重现了发育过程。另一方面,选定的重组hBMPs,即hBMP-2和hOP-1(hBMP-7),在临床环境中未能在原位骨骼部位诱导出显著的骨诱导作用。本综述提出,原位部位临床骨形成失败的原因是,在人类下颌部位植入hBMP-2、hOP-1以及hTGF-β并非通过胚胎发育的重现过程进行,最终导致“骨诱导原理”的临床转化失败。从生物学角度来看,TGF-β超家族的成骨蛋白的一个特性是通过胚胎骨发育的重现过程进行异位骨诱导。将重组hBMP-2和/或hOP-1递送至人类骨缺损部位失败,是因为骨诱导仅通过胚胎发育才有可能发生,而原位部位不存在这种情况,那里反应性细胞和血管供应有限。骨/骨髓器官的起始和组装遵循多步骤的分子和细胞级联反应,最终使骨骼生成的组装形态化,主导行走、身体直立、咀嚼功能、交配以及维持诸如骨髓和大脑半球等重要器官和组织。从胚胎学角度来看,骨通过间充质骨生成或软骨内骨生成形成。前一种途径主要通过诱导靶向间充质细胞聚集在颅面骨骼原基中凝结,从而塑造颅颌面部骨骼。一个关键步骤是围绕血管形成间充质细胞的凝结,因为血管引导骨的形成。软骨内骨生成首先通过构建软骨原基开始,发育中的骨将其用作生长和分化的支柱。软骨原基是一个特殊的管道,它启动分子和细胞间的细胞与细胞、细胞与受体的相互作用,以启动肥大软骨内的血管生成和毛细血管侵入、启动成骨细胞分化和骨沉积的软骨溶解、类骨质合成、骨髓发育以及诱导形成完整的矿化骨-骨髓器官。组装好的构建体储存着关键离子、几种结构蛋白,如骨粘连蛋白和纤连蛋白、成骨细胞分泌和活性的生物标志物,如骨钙素,以及一系列特殊的形态发生启动子,这些启动子从头启动分子和细胞级联反应,在异位部位诱导骨形成,重现胚胎发育。然而,在进化分子生物学背景下,这两种蛋白家族的多效性活动以及异位部位骨形成的诱导都是发育性的,因此当重组形态发生素单独植入原位骨骼缺损部位时不适合诱导骨形成,因为后者缺乏发育生物学平台。